$PTPI
Petros Pharmaceuticals, Inc. Stock $ptpi

$ptpi Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000141057823000575 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$2.518M	$798.1K	$5.992M
YoY Change	2.14%	-89.78%	-23.29%
Cost Of Revenue	$550.7K	$881.3K	$2.289M
YoY Change	16.6%	-44.9%	43.13%
Gross Profit	$1.967M	-$83.23K	$3.703M
YoY Change	-1.28%	-101.34%	-40.39%
Gross Profit Margin	78.13%	-10.43%	61.79%
Selling, General & Admin	$2.131M	$2.924M	$12.21M
YoY Change	-45.34%	-81.25%	-21.7%
% of Gross Profit	108.31%		329.74%
Research & Development	$319.1K	$177.8K	$1.740M
YoY Change	-21.28%	-90.06%	-2.7%
% of Gross Profit	16.22%		47.0%
Depreciation & Amortization	$826.8K	$916.3K	$5.599M
YoY Change	-47.03%	-45.83%	-18.6%
% of Gross Profit	42.03%		151.21%
Operating Expenses	$3.277M	$4.018M	$23.62M
YoY Change	32.44%	-83.44%	-2.64%
Operating Profit	-$1.309M	-$4.101M	-$19.92M
YoY Change	172.09%	-77.28%	10.35%
Interest Expense	-$75.85K	-$130.8K	-$121.8K
YoY Change	-124.71%	-101.44%	-101.34%
% of Operating Profit
Other Income/Expense, Net	-$75.85K		-$121.8K
YoY Change
Pretax Income	-$1.385M	-$4.232M	-$20.04M
YoY Change	695.06%	-52.91%	122.97%
Income Tax		-$10.50K	$0.00
% Of Pretax Income
Net Earnings	-$1.385M	-$4.221M	-$20.04M
YoY Change	695.04%	-53.03%	122.97%
Net Earnings / Revenue	-55.01%	-528.93%	-334.4%
Basic Earnings Per Share	-$0.66		-$9.68
Diluted Earnings Per Share	-$0.66	-$2.04	-$9.68
COMMON SHARES
Basic Shares Outstanding	2.089M	20.71M	2.070M
Diluted Shares Outstanding	2.089M		2.070M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.320M	$9.426M	$9.426M
YoY Change	-52.92%	-60.47%	-60.47%
Cash & Equivalents	$8.300M	$9.400M
Short-Term Investments
Other Short-Term Assets	$71.74K	$138.2K	$1.316M
YoY Change	-5.03%	25.47%	-64.62%
Inventory	$2.038M	$1.815M	$1.815M
Prepaid Expenses
Receivables	$2.400M	$2.110M	$2.110M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.90M	$14.67M	$14.67M
YoY Change	-48.2%	-51.98%	-51.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$36.62K	$39.18K	$397.7K
YoY Change	-21.82%	-20.69%	-24.25%
Goodwill
YoY Change
Intangibles	$11.42M	$12.24M
YoY Change	-51.88%	-51.59%
Long-Term Investments
YoY Change
Other Assets	$326.9K	$358.5K	$5.111M
YoY Change	-93.18%	-96.75%	-53.66%
Total Long-Term Assets	$16.67M	$17.75M	$17.75M
YoY Change	-42.58%	-51.82%	-51.82%
TOTAL ASSETS
Total Short-Term Assets	$13.90M	$14.67M	$14.67M
Total Long-Term Assets	$16.67M	$17.75M	$17.75M
Total Assets	$30.57M	$32.42M	$32.42M
YoY Change	-45.28%	-51.89%	-51.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.858M	$1.806M	$1.806M
YoY Change	-49.78%	-60.37%	-60.37%
Accrued Expenses	$3.609M	$3.635M	$3.622M
YoY Change	-34.53%	-69.6%	-84.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.106M	$1.090M	$1.090M
YoY Change	52.77%
Total Short-Term Liabilities	$6.885M	$7.068M	$7.068M
YoY Change	-33.08%	-77.19%	-77.19%
LONG-TERM LIABILITIES
Long-Term Debt	$8.014M	$8.388M	$8.388M
YoY Change	-15.45%
Other Long-Term Liabilities	$223.6K	$262.7K	$262.7K
YoY Change	-39.75%	-35.14%	-69.63%
Total Long-Term Liabilities	$223.6K	$262.7K	$8.651M
YoY Change	-39.75%	-35.14%	900.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.885M	$7.068M	$7.068M
Total Long-Term Liabilities	$223.6K	$262.7K	$8.651M
Total Liabilities	$15.12M	$15.72M	$15.72M
YoY Change	-24.9%	-50.64%	-50.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$92.10M	-$90.70M
YoY Change	29.9%	28.31%
Common Stock	$209.00	$208.00
YoY Change	-89.89%	-89.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.45M	$16.70M	$16.70M
YoY Change
Total Liabilities & Shareholders Equity	$30.57M	$32.42M	$32.42M
YoY Change	-45.28%	-51.89%	-51.89%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.385M	-$4.221M	-$20.04M
YoY Change	695.04%	-53.03%	122.97%
Depreciation, Depletion And Amortization	$826.8K	$916.3K	$5.599M
YoY Change	-47.03%	-45.83%	-18.6%
Cash From Operating Activities	-$748.4K	-$1.570M	-$12.80M
YoY Change	-85.88%	-81.09%	7.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-357.8K	-185.0K	-1.624M
YoY Change	-60.24%	-100.77%	-108.75%
NET CHANGE
Cash From Operating Activities	-748.4K	-1.570M	-12.80M
Cash From Investing Activities
Cash From Financing Activities	-357.8K	-185.0K	-1.624M
Net Change In Cash	-1.106M	-1.755M	-14.42M
YoY Change	-82.09%	-111.17%	-314.99%
FREE CASH FLOW
Cash From Operating Activities	-$748.4K	-$1.570M	-$12.80M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2455386
CY2022Q4	us-gaap	Inventory Net InventoryNet	1815113
CY2021Q4	us-gaap	Inventory Net InventoryNet	519649
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1316282
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001815903
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Registrant Name EntityRegistrantName	Petros Pharmaceuticals, Inc.
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2079387
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2068472
CY2020Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2021	ptpi	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39752
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1410058
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1185 Avenue of the Americas
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2022	dei	City Area Code CityAreaCode	973
CY2022	dei	Local Phone Number LocalPhoneNumber	242-0005
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	PTPI
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	12567127
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2088698
CY2022	dei	Auditor Firm AuditorFirmId	274
CY2022	dei	Auditor Name AuditorName	EisnerAmper LLP
CY2022	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9426264
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23847572
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2110246
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	3720088
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14667905
CY2021Q4	us-gaap	Assets Current AssetsCurrent	30542695
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39177
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49397
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12244484
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25293149
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	5111176
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	11029260
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	358472
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	475557
CY2022Q4	us-gaap	Assets Assets	32421214
CY2021Q4	us-gaap	Assets Assets	67390058
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1089683
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1806399
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4557969
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3634662
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11957384
CY2021Q4	ptpi	Accrued Inventory Purchases Current AccruedInventoryPurchasesCurrent	14203905
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	537232
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	260818
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7067976
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30980076
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8388093
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	460000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	262678
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	405018
CY2022Q4	us-gaap	Liabilities Liabilities	15718747
CY2021Q4	us-gaap	Liabilities Liabilities	31845094
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2079387
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2068472
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	208
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	207
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	107428652
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106233577
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90726393
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70688820
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	16702467
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35544964
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32421214
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67390058
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5992054
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7811264
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2289418
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1599566
CY2022	us-gaap	Gross Profit GrossProfit	3702636
CY2021	us-gaap	Gross Profit GrossProfit	6211698
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12209162
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15593233
CY2022	ptpi	Gain Loss On Settlement With Vivus GainLossOnSettlementWithVivus	3389941
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1740280
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1788491
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5598884
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6877990
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7460000
CY2022	us-gaap	Operating Expenses OperatingExpenses	23618385
CY2021	us-gaap	Operating Expenses OperatingExpenses	24259714
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-19915749
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-18048016
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	460000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	9430000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	14194
CY2021	ptpi	Interest Expense Senior Debt InterestExpenseSeniorDebt	368660
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	596018
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20037573
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8986676
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.68
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.68
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.25
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.25
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2070210
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1088977
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35544964
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1195076
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20037573
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	16702467
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	17469052
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21745003
CY2021	ptpi	Warrants Exercised During Period Value WarrantsExercisedDuringPeriodValue	4012435
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	187802
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1117348
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8986676
CY2021Q4	us-gaap	Shares Outstanding SharesOutstanding	35544964
CY2022	us-gaap	Profit Loss ProfitLoss	-20037573
CY2021	us-gaap	Profit Loss ProfitLoss	-8986676
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5598884
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6877990
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	7460000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-170816
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	148885
CY2022	ptpi	Inventory And Sample Inventory Reserve InventoryAndSampleInventoryReserve	-18998
CY2021	ptpi	Inventory And Sample Inventory Reserve InventoryAndSampleInventoryReserve	-200251
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12500
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	117085
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	103978
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	460000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	9430000
CY2022	ptpi	Adjustments For Deferred Revenue AdjustmentsForDeferredRevenue	211029
CY2021	ptpi	Adjustments For Deferred Revenue AdjustmentsForDeferredRevenue	70343
CY2022	ptpi	Gain Loss On Settlement With Vivus GainLossOnSettlementWithVivus	3389941
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1195076
CY2021	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1117348
CY2021	ptpi	Non Employee Stock Based Compensation NonEmployeeStockBasedCompensation	187802
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-515957
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2548698
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	835317
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-412744
CY2021	ptpi	Increase Decrease In Deposits1 IncreaseDecreaseInDeposits1	4576
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1648252
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	724785
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2751570
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1051587
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1802422
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2726403
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	65369
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-31291
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-142340
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-195902
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12797325
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11862031
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-1623983
CY2021	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	6653292
CY2021	ptpi	Payment Of Senior Debt End Of Term Fee PaymentOfSeniorDebtEndOfTermFee	-534237
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21745003
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4012435
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1623983
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18569909
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14421308
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6707878
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23847572
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17139694
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9426264
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23847572
CY2022	us-gaap	Interest Paid Net InterestPaidNet	596018
CY2021	us-gaap	Interest Paid Net InterestPaidNet	421821
CY2022	ptpi	Noncash Decrease In Accrued Expenses Related To Vivus Settlement NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement	-6520283
CY2022	ptpi	Noncash Decrease In Accrued Inventory Purchases Related To Vivus Settlement NoncashDecreaseInAccruedInventoryPurchasesRelatedToVivusSettlement	-14203905
CY2022	ptpi	Noncash Increase In Promissory Note Related To Vivus Settlement NoncashIncreaseInPromissoryNoteRelatedToVivusSettlement	10201758
CY2022	ptpi	Noncash Acquisition Active Pharmaceutical Ingredient Of Purchase Agreement NoncashAcquisitionActivePharmaceuticalIngredientOfPurchaseAgreement	-441149
CY2022	ptpi	Noncash Decrease In Api Purchase Commitment Related To Vivus Settlement NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement	5918084
CY2021	ptpi	Noncash Decrease In Api Purchase Commitment Related To Vivus Settlement NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement	114997
CY2022	ptpi	Noncash Decrease In Other Current Assets Api Purchase Commitment NoncashDecreaseInOtherCurrentAssetsApiPurchaseCommitment	755554
CY2021	ptpi	Noncash Decrease In Other Current Assets Api Purchase Commitment NoncashDecreaseInOtherCurrentAssetsApiPurchaseCommitment	-114997
CY2022	ptpi	Noncash Issuance Of Common Stock To Non Employee NoncashIssuanceOfCommonStockToNonEmployee	3
CY2020Q4	ptpi	Cash In Excess Of Certain Limit Subject To Adjustment As Provided In Merger Agreement CashInExcessOfCertainLimitSubjectToAdjustmentAsProvidedInMergerAgreement	20000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9400000
CY2022Q4	ptpi	Working Capital WorkingCapital	7600000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90700000
CY2022	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	9477776
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment, and the valuation of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.</p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to concentrations of credit risk includes cash. The Company maintains cash on deposit at U.S.-based banks in amounts which, at times, may be in excess of insured limits.</p>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2022Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	2300000
CY2021Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	3800000
CY2022	ptpi	Amount Of Returns As Reduction Of Gross Revenue AmountOfReturnsAsReductionOfGrossRevenue	9400000
CY2021	ptpi	Amount Of Returns As Reduction Of Gross Revenue AmountOfReturnsAsReductionOfGrossRevenue	8300000
CY2022	us-gaap	Revenue Practical Expedient Financing Component RevenuePracticalExpedientFinancingComponent	true
CY2021	ptpi	Shipping Costs ShippingCosts	0
CY2022	ptpi	Shipping Costs ShippingCosts	0
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	500000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	2757839
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	3363827
CY2022Q4	ptpi	Accounts Receivable Distribution Service Fees AccountsReceivableDistributionServiceFees	339094
CY2021Q4	ptpi	Accounts Receivable Distribution Service Fees AccountsReceivableDistributionServiceFees	371310
CY2022Q4	ptpi	Accounts Receivable Chargebacks Accruals AccountsReceivableChargebacksAccruals	1960
CY2022Q4	ptpi	Accounts Receivable Cash Discount Allowances AccountsReceivableCashDiscountAllowances	99671
CY2021Q4	ptpi	Accounts Receivable Cash Discount Allowances AccountsReceivableCashDiscountAllowances	159446
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	206868
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	377685
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2110246
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2455386
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1574683
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	359741
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	240430
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	159908
CY2022Q4	us-gaap	Inventory Net InventoryNet	1815113
CY2021Q4	us-gaap	Inventory Net InventoryNet	519649
CY2022Q4	ptpi	Inventory Finished Goods Valuation Reserves InventoryFinishedGoodsValuationReserves	364300
CY2021Q4	ptpi	Inventory Finished Goods Valuation Reserves InventoryFinishedGoodsValuationReserves	383298
CY2021Q4	ptpi	Inventory Raw Materials Valuation Reserves InventoryRawMaterialsValuationReserves	2872977
CY2022Q4	ptpi	Inventory Raw Materials Valuation Reserves InventoryRawMaterialsValuationReserves	2872977
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	109414
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	73223
CY2021Q4	ptpi	Prepaid Food And Drug Administration Fee Current PrepaidFoodAndDrugAdministrationFeeCurrent	831179
CY2022Q4	ptpi	Prepaid Coupon Fee Current PrepaidCouponFeeCurrent	71500
CY2021Q4	ptpi	Prepaid Coupon Fee Current PrepaidCouponFeeCurrent	71500
CY2022Q4	ptpi	Prepaid Purchase Commitment Asset Current PrepaidPurchaseCommitmentAssetCurrent	663984
CY2021Q4	ptpi	Prepaid Purchase Commitment Asset Current PrepaidPurchaseCommitmentAssetCurrent	1419538
CY2021Q4	ptpi	Due From Wholesalers Current DueFromWholesalersCurrent	609059
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	333158
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	605422
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	138226
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	110167
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1316282
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3720088
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32160919
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6867770
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25293149
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5588665
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	7460000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12244484
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3272746
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2800623
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1754328
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1442186
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1212871
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1761730
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12244484
CY2021Q4	ptpi	Accrued Price Protection AccruedPriceProtection	1853979
CY2022Q4	ptpi	Accrued Product Returns AccruedProductReturns	2311647
CY2021Q4	ptpi	Accrued Product Returns AccruedProductReturns	6192845
CY2022Q4	ptpi	Accrued Contract Rebates AccruedContractRebates	279018
CY2021Q4	ptpi	Accrued Contract Rebates AccruedContractRebates	379242
CY2021Q4	ptpi	Due Under License Agreement DueUnderLicenseAgreement	2267523
CY2022Q4	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	155081
CY2021Q4	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	479178
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	427500
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	527563
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	51620
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125392
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	409796
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	131662
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3634662
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11957384
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10201758
CY2022	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	9477776
CY2021	ptpi	Interest Expense Senior Debt InterestExpenseSeniorDebt	368660
CY2021Q1	ptpi	Renewal Term Of Agreement RenewalTermOfAgreement	P1Y
CY2022Q4	ptpi	Common Stock Potentially Issuable Upon Achievement Of Certain Milestones CommonStockPotentiallyIssuableUponAchievementOfCertainMilestones	1423209
CY2022	ptpi	Milestones Term For Achievement Of Stock Price And Market Capitalization MilestonesTermForAchievementOfStockPriceAndMarketCapitalization	P2Y
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	152166
CY2021Q4	ptpi	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance	260000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	260000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	158364
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	57433
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	514.30
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y10M24D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	61567
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.80
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	57433
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	514.30
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	61567
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.80
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M23D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.40
CY2022	ptpi	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y3D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7500
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.10
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	59067
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.02
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M14D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	50675
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.77
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M21D
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	296000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15000
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	32.10
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.30
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5000
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.40
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1195076
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1305150
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	441041
CY2021	ptpi	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	785356
CY2021	ptpi	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-201459
CY2021	ptpi	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-20823
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1004115
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1004115
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1004115
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20037573
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8986676
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2070210
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2070210
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1088977
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1088977
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.68
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.68
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.25
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.25
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1103420
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1077324
CY2022Q4	ptpi	Security Deposit For Sub Lease Received SecurityDepositForSubLeaseReceived	14000
CY2022	ptpi	Operating Lease Expense Per Month OperatingLeaseExpensePerMonth	7000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	179246
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	179246
CY2022	us-gaap	Sublease Income SubleaseIncome	84000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	358471
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	475557
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142340
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125579
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262677
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	405018
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	405017
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	530597
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.126
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.126
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	187739
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	184239
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	189374
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	155242
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	81107
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	82324
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	508047
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	103030
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	405017
CY2022Q4	ptpi	Operating Leases Future Minimum Payments Receivable Sub Lease Current OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseCurrent	84000
CY2022Q4	ptpi	Operating Leases Future Minimum Payments Receivable Sub Lease In Two Years OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseInTwoYears	56000
CY2022Q4	ptpi	Operating Leases Future Minimum Payments Receivable Sub Lease OperatingLeasesFutureMinimumPaymentsReceivableSubLease	140000
CY2022Q4	ptpi	Lessee Operating Lease Lease Not Yet Commenced Amount LesseeOperatingLeaseLeaseNotYetCommencedAmount	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0156
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0061
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0048
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.2231
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2398
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.5555
CY2022	ptpi	Effective Income Tax Rate Reconciliation Adjustment To Opening Deferrals EffectiveIncomeTaxRateReconciliationAdjustmentToOpeningDeferrals	0.00
CY2021	ptpi	Effective Income Tax Rate Reconciliation Adjustment To Opening Deferrals EffectiveIncomeTaxRateReconciliationAdjustmentToOpeningDeferrals	5.42
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0743
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	229348
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	186739
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	818127
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1006954
CY2022Q4	ptpi	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	7379214
CY2021Q4	ptpi	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	5669065
CY2022Q4	ptpi	Deferred Tax Assets Expenses Non Currently Deductible DeferredTaxAssetsExpensesNonCurrentlyDeductible	1140594
CY2021Q4	ptpi	Deferred Tax Assets Expenses Non Currently Deductible DeferredTaxAssetsExpensesNonCurrentlyDeductible	815108
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6013400
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3702789
CY2022Q4	ptpi	Deferred Tax Assets Interest Expense Limitation DeferredTaxAssetsInterestExpenseLimitation	226588
CY2021Q4	ptpi	Deferred Tax Assets Interest Expense Limitation DeferredTaxAssetsInterestExpenseLimitation	96920
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2882814
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2716370
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17053830
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12180037
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4873793
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17000000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	27400000
CY2022	ptpi	Percentage Of Future Utilization Of Operating Loss Carryforwards PercentageOfFutureUtilizationOfOperatingLossCarryforwards	0.80
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	51276
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	57543
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5992054
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2289418
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12209162
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	3389941
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1740280
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5598884
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	7460000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	460000
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	14194
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	596018
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20037573
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7811264
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1599566
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15593233
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1788491
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6877990
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	9430000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	368660
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8986676
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5992054
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7811264
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12244484
CY2022Q4	us-gaap	Assets Assets	32421214
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25293149
CY2021Q4	us-gaap	Assets Assets	67390058

Files In Submission

Name	View Source	Status
0001410578-23-000575-index-headers.html	Edgar Link	pending
0001410578-23-000575-index.html	Edgar Link	pending
0001410578-23-000575.txt	Edgar Link	pending
0001410578-23-000575-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmb-20221231.xsd	Edgar Link	pending
tmb-20221231x10k.htm	Edgar Link	pending
tmb-20221231xex23d1.htm	Edgar Link	pending
tmb-20221231xex31d1.htm	Edgar Link	pending
tmb-20221231xex31d2.htm	Edgar Link	pending
tmb-20221231xex32.htm	Edgar Link	pending
tmb-20221231_cal.xml	Edgar Link	unprocessable
tmb-20221231_def.xml	Edgar Link	unprocessable
tmb-20221231_lab.xml	Edgar Link	unprocessable
tmb-20221231_pre.xml	Edgar Link	unprocessable
tmb-20221231x10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTPI
Petros Pharmaceuticals, Inc. Stock $ptpi

2023 Q1 Form 10-K Financial Statement

#000141057823000575 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTPI Petros Pharmaceuticals, Inc. Stock $ptpi

2023 Q1 Form 10-K Financial Statement

#000141057823000575 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTPI
Petros Pharmaceuticals, Inc. Stock $ptpi